Choudary Iqra, Barr Paul M, Friedberg Jonathan
University of Rochester - James P. Wilmot Cancer Center, 601 Elmwood Ave, Rochester NY 14642, USA.
University of Rochester - James P. Wilmot Cancer Center, USA.
Ther Adv Hematol. 2015 Dec;6(6):282-94. doi: 10.1177/2040620715607415.
Over the last two decades, since the discovery of Drosophila mutants in 1995, much effort has been made to understand Aurora kinase biology. Three mammalian subtypes have been identified thus far which include the Aurora A, B and C kinases. These regulatory proteins specifically work at the cytoskeleton and chromosomal structures between the kinetochores and have vital functions in the early phases of the mitotic cell cycle. Today, there are multiple phase I and phase II clinical trials as well as numerous preclinical studies taking place looking at Aurora kinase inhibitors in both hematologic and solid malignancies. This review focuses on the preclinical and clinical development of Aurora kinase inhibitors in hematological malignancy and discusses their therapeutic potential.
在过去二十年中，自1995年发现果蝇突变体以来，人们为了解极光激酶生物学付出了诸多努力。迄今为止，已鉴定出三种哺乳动物亚型，包括极光激酶A、B和C。这些调节蛋白专门作用于细胞骨架以及动粒之间的染色体结构，在有丝分裂细胞周期的早期阶段发挥着至关重要的作用。如今，有多项I期和II期临床试验以及众多临床前研究正在进行，旨在研究极光激酶抑制剂在血液系统恶性肿瘤和实体恶性肿瘤中的应用。本综述重点关注极光激酶抑制剂在血液系统恶性肿瘤中的临床前和临床开发，并探讨其治疗潜力。
